Experts
EN
Allison Inquiry | Deanna McLeod | Day 3 September 10th, 2026
Research analyst Deanna McLeod, who runs an independent evidence-review firm, presents original analysis of Ontario health data obtained by FOIA, covering COVID case rates by vaccination status, immune and blood conditions, and reproductive health. She also questions the trial evidence and the policy framework behind the rollout. This is her first appearance and she returns later.
Deanna McLeod, who studied immunology and cognitive psychology at McMaster University, worked nearly a decade in pharmaceutical oncology sales and marketing before founding an independent medical research firm in 2000. Her firm has published over 50 peer-reviewed guidelines and systematic reviews, supported an audit of Alberta's COVID-19 response, and recently presented cancer trend findings to the US president's cancer panel. She says she is testifying, though not a doctor, because clinicians have been censored, and describes a shift under emergency orders from an individual to a collective risk-benefit framework and the influence of public-private partnerships. McLeod reviews the six-month Pfizer trial publication, arguing it showed a small absolute reduction in COVID cases alongside more side effects, including cardiovascular deaths. She then presents Ontario data, obtained by FOIA with the Canadian Citizens Care Alliance, showing higher COVID case rates in vaccinated and boosted groups after Omicron, short-term infection clusters after rollout, and rises in immune-related conditions, iron deficiency anemia, anaphylaxis and Bell's palsy. She says she cannot assert causation from population data. She also presents ovarian inflammation and pregnancy-related figures, and challenges the reporting of miscarriage data. The chair runs out of time and says she may be recalled. This is her first appearance. She returns later at https://youtu.be/NA10OUbjHxs.
Deanna McLeod, who studied immunology and cognitive psychology at McMaster University, worked nearly a decade in pharmaceutical oncology sales and marketing before founding an independent medical research firm in 2000. Her firm has published over 50 peer-reviewed guidelines and systematic reviews, supported an audit of Alberta's COVID-19 response, and recently presented cancer trend findings to the US president's cancer panel. She says she is testifying, though not a doctor, because clinicians have been censored, and describes a shift under emergency orders from an individual to a collective risk-benefit framework and the influence of public-private partnerships. McLeod reviews the six-month Pfizer trial publication, arguing it showed a small absolute reduction in COVID cases alongside more side effects, including cardiovascular deaths. She then presents Ontario data, obtained by FOIA with the Canadian Citizens Care Alliance, showing higher COVID case rates in vaccinated and boosted groups after Omicron, short-term infection clusters after rollout, and rises in immune-related conditions, iron deficiency anemia, anaphylaxis and Bell's palsy. She says she cannot assert causation from population data. She also presents ovarian inflammation and pregnancy-related figures, and challenges the reporting of miscarriage data. The chair runs out of time and says she may be recalled. This is her first appearance. She returns later at https://youtu.be/NA10OUbjHxs.
